Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Despina Eleftheriou, Yolanda Collaco Moraes, Cara Purvis, Molly Pursell, Marta Merida Morillas, Robin Kahn, Maria Mossberg, Filip Kucera, Robert Tulloh, Joseph F. Standing, Veronica Swallow, Rachael McCormack, Jethro Herberg, Michael Levin, Mandy Wan, Nigel Klein, Roisin Connon, Ann Sarah Walker, Paul Brogan

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science